Evotec Faces Analyst Target Cut Amid Restructuring Phase
Published on 03/30/2026 at 04:33 | Redaktion boerse-global.de
Analysts at Berenberg Bank have revised their valuation for Evotec SE, lowering their price target for the Hamburg-based drug discovery specialist while maintaining a positive long-term stance. The adjustment comes as the company navigates a significant corporate overhaul, known as the "Horizon" program, which is expected to weigh on near-term financial performance.
Maintaining a "Buy" Despite Near-Term Headwinds
In a recent research note, Berenberg strategists reaffirmed their "Buy" recommendation on Evotec shares. However, they set a new price target of €9.70, down from their previous assessment. This revision primarily reflects the anticipated short-term costs and operational complexity associated with the ongoing restructuring initiative. The "Horizon" program is designed to optimize the company's cost structure and secure long-term profitability, but its implementation phase is currently creating margin pressure.
The bank's analysts continue to see substantial upside potential for the stock. This outlook is highlighted by the significant gap between the new target and the recent trading price. Evotec shares concluded Friday's session at €4.26, following a decline of approximately 27% over the past month.
Should investors sell immediately? Or is it worth buying Evotec?
Market and Internal Challenges Converge
Evotec's path forward is shaped by both its internal transformation and a demanding external market environment. Industry-wide factors, such as political pressure on drug pricing stemming from U.S. negotiations, are affecting sentiment across the biopharma value chain. Consequently, investors are keenly awaiting concrete updates to gauge the true progress of Evotec's strategic shift.
Management has scheduled two key events that will serve as critical checkpoints for the restructuring's validity:
* April 8, 2026: Publication of the Group's Annual Report
* May 6, 2026: Release of the Q1 interim statement
These disclosures will be scrutinized for evidence of how effectively the "Horizon" measures are taking hold. A primary focus will be the company's financial guidance for the remainder of 2026, which should indicate whether existing pharmaceutical partnerships can offset the margin erosion occurring during this transitional period.
Ad
Evotec Stock: New Analysis - 30 March
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
